ALNY News and Press, Alnylam Pharmaceuticals Inc. From 02/05/24

2024-02-05 14:00:00 ET Summary Welcome to another installment of our monthly Rare Stock Picks series. Today, we're highlighting January 2024 investment picks you may have missed. As you know, some Seeking Alpha analysts are more discerning by nature. Others are finding compelling ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2023 on Thursday, February 15, 2024, before the U.S. financial markets open. Management will provide...

2024-01-28 11:52:19 ET Summary Baillie Gifford's 13F portfolio value increased from ~$110B to ~$126B this quarter. The top three holdings are MercadoLibre, NVIDIA, and Amazon.com, accounting for ~17% of the portfolio. Baillie Gifford increased stakes in PDD Holdings, Shopify, ...

2024-01-27 15:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-12 10:35:06 ET Summary Pfizer's drug tafamidis has shown positive results in treating transthyretin amyloidosis cardiomyopathy (ATTR-CM), but there is still room for improvement. Alnylam's gene silencer treatments, ONPATTRO and vutrisiran, have shown promise in reducing le...

2024-01-10 12:09:02 ET More on Regeneron Pharmaceuticals Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript) Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade) Regeneron Pharmaceuticals Inc. (REGN) Am...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, said today that Chief Executive Officer Yvonne Greenstreet has been selected as the 2024 Woman of the Year by the Healthcare Businesswomen’s Association (HBA). The announcement was made last evening at t...

2024-01-08 02:05:37 ET More on Alnylam Pharmaceuticals Alnylam Pharmaceuticals: R&D Day Reveals Ambitious Plans Alnylam: Q3 Journey, Financial Growth, And Regulatory Hurdles Alnylam reports positive Phase 2 data for hypertension drug Alnylam Pharmaceutica...

– Achieved Full Year 2023 Preliminary Global Net Product Revenues of $1,241 Million for ONPATTRO ® , AMVUTTRA ® , GIVLAARI ® , and OXLUMO ® , Representing 39% Annual Growth (39% Using Constant Exchange Rate**) – – Maintained Strong ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 9:45 am PT (12:45 pm ...